Current assets increased 89.0%
Current assets changed +89.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current assets changed +89.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +99.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Revenue changed -100.0% from the comparable as-filed period.
Current liabilities changed +25.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed -186.6% from the comparable as-filed period.
Operating income changed -59.1% from the comparable as-filed period.
Operating cash flow changed -187.4% from the comparable as-filed period.
Shares outstanding changed +18.7% from the comparable as-filed period. The change ranks at the 75th percentile of 8 prior comparable changes.
Net income changed -60.6% from the comparable as-filed period.
Working capital / assets changed +998 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Research & development changed +73.4% from the comparable as-filed period.
Working capital / assets changed -1618 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed +62050 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed +466.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -62.9% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed +52.4% from the comparable as-filed period.
Net income changed +20.1% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Cost of revenue changed +466.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Capex / revenue changed -533 basis points from the comparable as-filed period.
Total assets changed +45.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating income changed +10.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Shares outstanding changed +16.3% from the comparable as-filed period. The change ranks at the 75th percentile of 8 prior comparable changes.
SBC / revenue changed -10519 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed +10.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash flow changed +9.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Trade receivables changed -50.0% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.